The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced on January 18 that enrollment into a large international HIV/AIDS trial comparing continuous antiretroviral therapy with episodic drug treatment guided by levels of CD4+ cells has been stopped. Enrollment was stopped because those patients receiving episodic therapy had twice the risk of disease progression (the development of clinical AIDS or death), the major outcome of the study.
Read the full story at http://www.nih.gov/news/pr/jan2006/niaid-18.htm.
skip to main |
skip to sidebar
Saint Mary's Health Care
Grand Rapids, Michigan
